{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:12:31Z","timestamp":1787425951524,"version":"build-2736575974"},"reference-count":35,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T00:00:00Z","timestamp":1632009600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,8,31]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The COVID-19 pandemic has emerged worldwide. Although several medications have been approved for treating moderate-to-severe COVID-19, very few treatment strategy has been established for patients with mild COVID-19 who do not require oxygen administration. Clarithromycin is a macrolide antimicrobial agent that has been widely used for bacterial respiratory infectious diseases. Clarithromycin also acts an immunomodulating drug and suppresses cytokine storms in viral respiratory diseases, including influenza. In this study, we aim to evaluate the efficacy of clarithromycin in patients with mild COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is an exploratory, multicentre, open-label, randomised controlled trial. This study was initiated in May 2021 and will end in July 2022. Patients with mild COVID-19 pneumonia who do not require oxygen administration will be enrolled and randomly assigned in a 1:1:1 ratio to group A (administration of clarithromycin 800\u2009mg\/day), group B (administration of clarithromycin 400\u2009mg\/day) or group C (standard treatment without clarithromycin). The planned number of enrolled patients is 60 (20 patients \u00d7 three groups). The primary endpoint is the number of days required to improve the clinical symptoms as measured by the severity score. Secondary endpoints include days for recovery of the body temperature, proportion of patients with oxygen administration, inflammatory cytokines, viral load, serum immunoglobulins, peripheral blood lymphocytes, blood biomarkers and pneumonia infiltrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol was approved by the Clinical Research Review Board of Nagasaki University in accordance with the Clinical Trials Act in Japan. The study will be conducted in accordance with the Declaration of Helsinki, the Clinical Trials Act and other current legal regulations in Japan. Written informed consent will be obtained from all the participants. The results of this study will be reported as journal publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>jRCTs071210011.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-053325","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T13:55:17Z","timestamp":1632232517000},"page":"e053325","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of clarithromycin in patients with mild COVID-19 pneumonia not receiving oxygen administration: protocol for an exploratory, multicentre, open-label, randomised controlled trial (CAME COVID-19 study)"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1357-1676","authenticated-orcid":false,"given":"Kazuko","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"},{"name":"Clinical Research Center, National Organization Hospital Nagasaki Medical Center, Omura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7577-476X","authenticated-orcid":false,"given":"Noriho","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2955-4432","authenticated-orcid":false,"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Infection Control and Education Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"2025121400405016000_11.9.e053325.1","unstructured":"Ministry of Health, Labour and Welfare in Japan . Novel coronavirus (COVID-19), 2021. Available: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000164708_00079.html"},{"key":"2025121400405016000_11.9.e053325.2","unstructured":"Ministry of Health, Labour and Welfare in Japan . 11 knowledge of the \"now\" about the novel coronavirus infectious disease (August, 2021 version), 2021. Available: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00256.html"},{"key":"2025121400405016000_11.9.e053325.3","article-title":"Dexamethasone in hospitalized patients with Covid-19 - preliminary report","volume":"17","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121400405016000_11.9.e053325.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025121400405016000_11.9.e053325.5","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2429"},{"key":"2025121400405016000_11.9.e053325.6","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035002"},{"key":"2025121400405016000_11.9.e053325.7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab292","article-title":"Effectiveness of severe acute respiratory syndrome coronavirus 2 monoclonal antibody infusions in high-risk outpatients","volume":"8","author":"Piccicacco","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025121400405016000_11.9.e053325.8","article-title":"Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany","volume":"in press","author":"Koehler","year":"2021","journal-title":"Infection"},{"key":"2025121400405016000_11.9.e053325.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-017-0629-x"},{"key":"2025121400405016000_11.9.e053325.10","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa041"},{"key":"2025121400405016000_11.9.e053325.11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"2025121400405016000_11.9.e053325.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030340"},{"key":"2025121400405016000_11.9.e053325.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"2025121400405016000_11.9.e053325.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.10.017","article-title":"Survival benefit associated with clarithromycin in severe community-acquired pneumonia: a matched comparator study","volume":"55","author":"Kyriazopoulou","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025121400405016000_11.9.e053325.15","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.1.82"},{"key":"2025121400405016000_11.9.e053325.16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05798-11"},{"key":"2025121400405016000_11.9.e053325.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.012"},{"key":"2025121400405016000_11.9.e053325.18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.resinv.2017.07.005","article-title":"The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases","volume":"55","author":"Yatera","year":"2017","journal-title":"Respir Investig"},{"key":"2025121400405016000_11.9.e053325.19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00461-x"},{"key":"2025121400405016000_11.9.e053325.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106143"},{"key":"2025121400405016000_11.9.e053325.21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"2025121400405016000_11.9.e053325.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31862-6"},{"key":"2025121400405016000_11.9.e053325.23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMoa2019014","article-title":"Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19","volume":"383","author":"Cavalcanti","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121400405016000_11.9.e053325.24","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_D.137"},{"key":"2025121400405016000_11.9.e053325.25","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/31.suppl_E.153"},{"key":"2025121400405016000_11.9.e053325.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03299.x"},{"key":"2025121400405016000_11.9.e053325.27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1620\/tjem.220.59","article-title":"Low expression of T-cell co-stimulatory molecules in bone marrow-derived dendritic cells in a mouse model of chronic respiratory infection with Pseudomonas aeruginosa","volume":"220","author":"Mukae","year":"2010","journal-title":"Tohoku J Exp Med"},{"key":"2025121400405016000_11.9.e053325.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2009.08.004"},{"key":"2025121400405016000_11.9.e053325.29","unstructured":"Ministry of Health, Labour and Welfare in Japan . COVID-19 infectious disease treatment guidelines (ver.5.1), 2021. Available: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000121431_00111.html"},{"key":"2025121400405016000_11.9.e053325.30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"2025121400405016000_11.9.e053325.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"2025121400405016000_11.9.e053325.32","unstructured":"Japanese Respiratory Society . The JRS guidelines for the management of community-acquired pneumonia in adults. Japanese Respiratory Society 2007 https:\/\/www.jrs.or.jp\/modules\/basicauth\/index.php?file=adult_pneumonia1-3.pdf"},{"key":"2025121400405016000_11.9.e053325.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-321852"},{"key":"2025121400405016000_11.9.e053325.34","unstructured":"Ministry of Health, Labour and Welfare in Japan . Ethical guidelines for medical and health research involving human subjects, 2021. Available: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/hokabunya\/kenkyujigyou\/i-kenkyu\/index.html"},{"key":"2025121400405016000_11.9.e053325.35","doi-asserted-by":"crossref","first-page":"204020662096171","DOI":"10.1177\/2040206620961712","article-title":"Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond","volume":"28","author":"Poddighe","year":"2020","journal-title":"Antivir Chem Chemother"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-053325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T08:40:59Z","timestamp":1765701659000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-053325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,21]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bmjopen-2021-053325"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-053325","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.06.02.21258257","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}